SEATTLE--(BUSINESS WIRE)--Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application. The Phase 1b randomized, double-blind, placebo-controlled, crossover study will evaluate RLS103 in patients with photosensitive epilepsy as a model for REST. RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of psychiatric and neurological disorders. Epilepsy study startup is underway.
“As the parent of a child with epilepsy, I recognize the need for a product that can terminate a seizure as soon as possible, without sedation,” said Mark Theeuwes, President and CEO of Receptor Life Science. “RLS103 could address that need as the first non-scheduled, non-sedating seizure rescue therapy. Advancing our lead drug candidate, RLS103, into a second proof-of-concept clinical study demonstrates our continued commitment to treating central nervous system conditions in collaboration with FDA.”
“Many patients with epilepsy have recognizable auras that precede a seizure,” said Orrin Devinsky, MD, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine. “A treatment capable of terminating a seizure at the aura stage would be a life-changing therapy for these patients. This study is designed to be the first proof-of-concept clinical trial of RLS103 in epilepsy, and will be a study of significant interest for epileptologists and patient communities.”
According to the Epilepsy Foundation, seizure disorder affects about 3.4 million people in the United States.
About Receptor Life Sciences
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval, see www.receptorlife.com.
